Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and genetic predictors of temozolomide-induced severe myelotoxicity in adult diffuse glioma: a case-control study.

Journal of neuro-oncology - 20 Feb 2026

Malhotra Rahat, Moitra Prithwijit, Chatterjee Abhishek, Kota Priti Khatri, Dasgupta Archya, Epari Sridhar, Menon Nandini, Kowtal Pradnya, Sarin Rajiv, Gupta Tejpal

Abstract excerpt

PURPOSE: Several clinical and genetic factors including single nucleotide polymorphisms (SNP) in the O6-methylguanine-DNA methyltransferase (MGMT) gene are associated with increased risk of temozolomide (TMZ) induced myelotoxicity. We have previously reported substantially higher frequency of variant T allele of L84F (SNP in MGMT gene) in Indian patients with clinically relevant myelotoxicity compared to normal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dacarbazine

Share to DNA Modification Methylases

Share to DNA Repair Enzymes

Share to Glioma

Share to Temozolomide

Share to Tumor Suppressor Proteins

Source

Identifiers

PMID: 41718852
DOI: 10.1007/s11060-026-05474-x

Genes

MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and genetic predictors of temozolomide-induced severe myelotoxicity in adult diffuse glioma: a case-control study.PMID 41718852Read ↗

Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study.Semantic proximity Read ↗

Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.Semantic proximity Read ↗

MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case.Semantic proximity Read ↗

Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors.Semantic proximity Read ↗

Temozolomide-induced severe myelosuppression: analysis of clinically associated polymorphisms in two patients.Semantic proximity Read ↗

Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China.Semantic proximity Read ↗

Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population.Semantic proximity Read ↗

miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferaseSemantic proximity Read ↗

Genetic associations of docetaxel-based chemotherapy-induced myelosuppression in Chinese Han population.Semantic proximity Read ↗

Quantitative assessment of the association between XRCC3 C18607T polymorphism and glioma risk.Semantic proximity Read ↗

Evaluating the role of GSTP1 genetic polymorphism (rs1695, 313A>G) as a predictor in cyclophosphamide-induced toxicities.Semantic proximity Read ↗

TPMT*3C as a Predictor of 6-Mercaptopurine-Induced Myelotoxicity in Thai Children with Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.